Compare Quest Diagnostics Inc (DGX) vs Levi Strauss & Co. (LEVI) Price & Performance

Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.

DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.

Levi Strauss (LEVI) trades at $19.51, down 4.97% on the day, with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 62.81% gross margins and 8.83% net income margin, supported by four consecutive quarterly earnings beats. Analyst consensus remains strongly bullish with a $29 price target representing 49% upside potential. Recent developments include the appointment of a new CFO and continued momentum in denim demand driving revenue growth.

The stock presents a compelling value opportunity with attractive valuation multiples (P/E 12.53, P/S 1.12) and strong cash flow generation. However, near-term technical weakness and recent cybersecurity concerns require monitoring. The company's direct-to-consumer strategy and international expansion provide growth catalysts, though execution risks and market volatility remain considerations for investors.